GNTA vs HUMA

Genenta Science S.p.A. vs Humacyte, Inc. — Valuation Comparison 2026

GNTA

Biological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
Quality
4.7
out of 10
Value Trap
12
SAFE
Price
$1.03
Last close
Models
7/13
Active
VS

HUMA

Biological Products, (No Diagnostic Substances)
Humacyte, Inc.
Quality
3.5
out of 10
Value Trap
36
LOW
Price
$1.30
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType GNTA Fair ValueGNTA Upside HUMA Fair ValueHUMA Upside
Bayesian DCF Intrinsic $0.23 -77.6% $0.24 -81.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.80 -22.7% $0.36 -72.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GNTA vs HUMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GNTA vs HUMA — Which Stock Is More Undervalued?

GNTA scores higher with a 4.7/10 quality rating vs HUMA's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Genenta Science S.p.A. (GNTA) and Humacyte, Inc. (HUMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GNTA currently trades at $1.03 with a QOC of 4.7/10, while HUMA trades at $1.30 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).